Overview

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Status:
Terminated

Trial end date:
2015-04-30

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in participants with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Vemurafenib